Thermo Fisher price target lowered to $470 from $620 at Argus

Argus lowered the firm’s price target on Thermo Fisher (TMO) to $470 from $620 but keeps a Buy rating on the shares. Excluding the academic and government sector, the company’s end market conditions are improving as the biopharma industry develops new biologic medicines, the analyst tells investors in a research note. Thermo Fisher is also navigating headwinds arising from trade tariffs and policy changes from the U.S. administration, Argus adds.